{"id":"W2609430257","doi":"10.1093/annonc/mdx173","title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of California, San Francisco; University of Warwick; Cancer Research UK; Sanofi","keywords":"Medicine; Epirubicin; Docetaxel; Bevacizumab; Fluorouracil; Cyclophosphamide; Oncology; Internal medicine; Chemotherapy; Breast cancer; Disease; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001660474,0.0007160573,0.001188875,0.0002172567,0.0002766478,0.0008889866,0.0005179933,0.0007846634,0.001674462],"category_scores_gemma":[0.001503248,0.0002782898,0.001333775,0.0002260228,0.0006022984,0.0005227121,0.0003280834,0.00177977,0.0002923152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001127585,"about_ca_system_score_gemma":0.0008119336,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009963523,"about_ca_topic_score_gemma":0.003659738,"domain_scores_codex":[0.9993839,0.0003624466,0.0000301118,0.00009792877,0.00004765536,0.00007792611],"domain_scores_gemma":[0.9991721,0.0002000238,0.000203674,0.00006756829,0.00004089194,0.0003158665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9564773,0.004037249,0.006159887,0.0002037853,0.0009216694,0.00005672119,0.0000696288,0.0008109782,0.003262396,0.00007251244,0.0008145818,0.02711333],"study_design_scores_gemma":[0.6297954,0.2997505,0.06134086,0.0001202652,0.002491328,0.0002830655,0.00007972756,0.001919001,0.001647923,0.0004761361,0.002055905,0.00003981216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962436,0.002080345,0.0001321975,0.0002661444,0.00009733668,0.0002117837,0.0003094708,0.00001622304,0.0006428775],"genre_scores_gemma":[0.9966429,0.0007747359,0.000315432,0.0002610272,0.0001288672,0.0003500429,0.0007098036,0.000005394067,0.0008116991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001674462,"threshold_uncertainty_score":0.008781552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02595071290210165,"score_gpt":0.3272912708754922,"score_spread":0.3013405579733905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}